Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone

The purpose of this trial is to compare efficacy and safety of azathioprine vs. placebo in new cases of pemphigus vulgaris treated with prednisolone.

Official Title: Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Azathioprine in New Cases of Pemphigus Vulgaris Receiving Prednisolone

Randomized Double Blind Controlled Trial of Azathioprine versus Placebo in new cases of Pemphigus Vulgaris treated with Prednisolone

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver), Placebo Controlled, Parallel Assignment, Safety/Efficacy Study

Condition Intervention Phase Pemphigus Vulgaris Drug: Azathioprine Drug: Prednisolone Other: Placebo Phase II

Inclusion criteria

• Lesions clinically consistent with pemphigus vulgaris
• Diagnosis confirmed by histology in terms of acantholysis within past month
• Positive DIF

Exclusion criteria

• Any nursing or pregnant woman
• Any history of chronic diseases including liver disease, Chronic Renal Failure, Chronic Heart Failure or Ischemic Heart Disease
• Present diagnosis of hepatitis confirmed by serology or elevated hepatic enzymes;
• Clinically significant concurrent medical disease or laboratory abnormalities evidenced by one or more of the following:
• Hepatobiliary AST or ALT ≥ 1.5 × upper limit of normal (ULN);alkaline phosphatase ≥ 1.5 × ULN; or, total bilirubin > 90% of the ULN;
• Renal serum creatinine > 1.5 mg/dL; or, significant proteinuria > 2+ on urinary dip test;
• Hematologic hemoglobin < 11 mg/dL; leukocytes < 3.5 × 109/L; neutrophils < 1.5 × 109/L; or, platelets < 100 × 109/L; Presence of anemia, leukopenia or thrombocytopenia
• Any sign of patient's non-compliance
• Known hypersensitivity to study drugs, prednisone or azathioprine
• Participating in another clinical trial at the time of screening and enrollment